Cover Image
市場調查報告書

拉薩熱:開發中產品分析

Lassa Fever - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363115
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
拉薩熱:開發中產品分析 Lassa Fever - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 54 Pages
簡介

本報告提供拉薩熱治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

拉薩熱概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

拉薩熱:企業開發中的治療藥

拉薩熱:大學/機關研究中的治療藥

拉薩熱:開發中產品概況

  • 初期階段的產品

拉薩熱:企業開發中的產品

拉薩熱:大學/機關研究中的產品

rassa環境熱能治療藥的開發企業

  • Arno Therapeutics, Inc.
  • Celgene Corporation
  • Etubics Corporation
  • Kineta, Inc.
  • Profectus BioSciences, Inc.
  • SIGA Technologies, Inc.

拉薩熱:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

拉薩熱:暫停中的計劃

拉薩熱:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8197IDB

Summary

Global Markets Direct's, 'Lassa Fever - Pipeline Review, H1 2016', provides an overview of the Lassa Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lassa Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lassa Fever and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lassa Fever
  • The report reviews pipeline therapeutics for Lassa Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Lassa Fever therapeutics and enlists all their major and minor projects
  • The report assesses Lassa Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Lassa Fever

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lassa Fever
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lassa Fever pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Lassa Fever Overview
  • Therapeutics Development
    • Pipeline Products for Lassa Fever - Overview
    • Pipeline Products for Lassa Fever - Comparative Analysis
  • Lassa Fever - Therapeutics under Development by Companies
  • Lassa Fever - Therapeutics under Investigation by Universities/Institutes
  • Lassa Fever - Pipeline Products Glance
    • Early Stage Products
  • Lassa Fever - Products under Development by Companies
  • Lassa Fever - Products under Investigation by Universities/Institutes
  • Lassa Fever - Companies Involved in Therapeutics Development
    • Arno Therapeutics, Inc.
    • Celgene Corporation
    • Etubics Corporation
    • Kineta, Inc.
    • Profectus BioSciences, Inc.
    • SIGA Technologies, Inc.
  • Lassa Fever - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-11050 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DEF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FBH-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lassa fever vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lassa fever vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LHF-535 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Lassa Fever - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-193 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lassa Fever - Dormant Projects
  • Lassa Fever - Product Development Milestones
    • Featured News & Press Releases
      • May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials
      • Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals
      • May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lassa Fever, H1 2016
  • Number of Products under Development for Lassa Fever - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Lassa Fever - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Lassa Fever - Pipeline by Celgene Corporation, H1 2016
  • Lassa Fever - Pipeline by Etubics Corporation, H1 2016
  • Lassa Fever - Pipeline by Kineta, Inc., H1 2016
  • Lassa Fever - Pipeline by Profectus BioSciences, Inc., H1 2016
  • Lassa Fever - Pipeline by SIGA Technologies, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Lassa Fever - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Lassa Fever, H1 2016
  • Number of Products under Development for Lassa Fever - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top